nitrendipine has been researched along with Cardiovascular Diseases in 20 studies
Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.
nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.
Cardiovascular Diseases: Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The introduction of phosphodiesterase-5 inhibitors as sildenafil, tadalafil, or vardenafil, has tremendously improved the treatment of erectile dysfunction." | 9.13 | Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition. ( Jung, F; Leithäuser, B; Park, JW, 2008) |
| "In hypertensive stroke patients, for the same level of blood pressure control, eprosartan will be more effective than nitrendipine in reducing cerebrovascular and cardiovascular morbidity and mortality." | 9.11 | Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). ( Berger, J; Diener, HC; Dominiak, P; Hammersen, F; Kulschewski, A; Lüders, S; Plate, K; Schrader, J; Zidek, W, 2005) |
| "We examined the relation of serum creatinine and uric acid to mortality and cardiovascular disease in older (aged >/=60 years) Chinese patients with isolated systolic hypertension (systolic/diastolic blood pressure >/=160/<95 mm Hg)." | 9.09 | Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. ( Birkenhäger, WH; Fagard, RH; Gong, L; Liu, L; Staessen, JA; Wang, JG, 2001) |
| "Eprosartan is an angiotensin II receptor antagonist (angiotensin II receptor blocker [ARB]) used in the treatment of hypertension." | 8.85 | Eprosartan: a review of its use in hypertension. ( Plosker, GL, 2009) |
| "Felodipine alone was sufficient to control blood pressure in 90% of patients, while 50% of patients who were receiving diuretic therapy required a second agent for control." | 6.66 | Cardiovascular-risk reduction: initial diuretic therapy compared with calcium-antagonist (felodipine) therapy for primary hypertension. ( Bruce, A; Jennings, GL; Sudhir, K, 1989) |
| "The introduction of phosphodiesterase-5 inhibitors as sildenafil, tadalafil, or vardenafil, has tremendously improved the treatment of erectile dysfunction." | 5.13 | Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition. ( Jung, F; Leithäuser, B; Park, JW, 2008) |
| "In hypertensive stroke patients, for the same level of blood pressure control, eprosartan will be more effective than nitrendipine in reducing cerebrovascular and cardiovascular morbidity and mortality." | 5.11 | Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES). ( Berger, J; Diener, HC; Dominiak, P; Hammersen, F; Kulschewski, A; Lüders, S; Plate, K; Schrader, J; Zidek, W, 2005) |
| "Nitrendipine-based antihypertensive therapy is particularly beneficial in older patients with diabetes and isolated systolic hypertension." | 5.09 | Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. ( Antikainen, R; Birkenhäger, WH; Bulpitt, CJ; Fagard, R; Fletcher, AE; Forette, F; Goldhaber, A; Palatini, P; Rastenyte, D; Sarti, C; Thijs, L; Tuomilehto, J, 1999) |
| "In elderly Chinese patients with isolated systolic hypertension, stepwise antihypertensive drug treatment, starting with the dihydropyridine calcium channel blocker nitrendipine, improved prognosis." | 5.09 | Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. ( Gong, L; Liu, L; Staessen, JA; Wang, JG, 2000) |
| "We examined the relation of serum creatinine and uric acid to mortality and cardiovascular disease in older (aged >/=60 years) Chinese patients with isolated systolic hypertension (systolic/diastolic blood pressure >/=160/<95 mm Hg)." | 5.09 | Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension. ( Birkenhäger, WH; Fagard, RH; Gong, L; Liu, L; Staessen, JA; Wang, JG, 2001) |
| "Stepwise antihypertensive drug treatment, starting with the dihydropiridine calcium-channel blocker nitrendipine, improves prognosis in elderly patients with isolated systolic hypertension." | 5.09 | Dihydropyridine calcium-channel blockers for antihypertensive treatment in older patients--evidence from the Systolic Hypertension in Europe Trial. ( Celis, H; Fagard, RH; Gasowski, J; Staessen, JA; Thijs, L; Wang, JG, 2001) |
| "In the double-blind Systolic Hypertension in Europe (Syst-Eur) Trial, active treatment was initiated with nitrendipine (10 to 40 mg/d) with the possible addition of enalapril (5 to 20 mg/d) and/or hydrochlorothiazide (12." | 5.08 | Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension. ( Arabidze, G; Babeanu, S; Birkenhäger, WH; Bulpitt, CJ; Davidson, C; de Leeuw, PW; Efstratopoulos, AD; Fagard, RH; Fletcher, AE; Fogari, R; Gil-Extremera, B; Jääskivi, M; Kawecka-Jaszcz, K; Nachev, C; Petrie, JC; Seux, ML; Staessen, JA; Thijs, L; Tuomilehto, J; Webster, J; Yodfat, Y, 1998) |
| "Eprosartan is an angiotensin II receptor antagonist (angiotensin II receptor blocker [ARB]) used in the treatment of hypertension." | 4.85 | Eprosartan: a review of its use in hypertension. ( Plosker, GL, 2009) |
| " As the first dihydropyridine available for use in the United States, nifedipine controls angina and hypertension with minimal depression of cardiac function." | 4.77 | Differential effects of 1,4-dihydropyridine calcium channel blockers: therapeutic implications. ( Katz, AM; Leach, NM, 1987) |
| " In secondary prevention, an additional risk reduction is modeled for eprosartan according to the results of the MOSES study ("Morbidity and Mortality after Stroke--Eprosartan Compared to Nitrendipine for Secondary Prevention")." | 3.75 | Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model. ( Diener, HC; Gradl, B; Greiner, W; Jönsson, B; Lindgren, P; Lüders, S; Schrader, J; Schwander, B; Villar, FA; Zöllner, Y, 2009) |
| "Felodipine alone was sufficient to control blood pressure in 90% of patients, while 50% of patients who were receiving diuretic therapy required a second agent for control." | 2.66 | Cardiovascular-risk reduction: initial diuretic therapy compared with calcium-antagonist (felodipine) therapy for primary hypertension. ( Bruce, A; Jennings, GL; Sudhir, K, 1989) |
| "Bepridil is an effective antianginal drug, but, because of its proarrhythmic potential, it should probably not be used as a first-line agent." | 2.37 | Nicardipine, nitrendipine, and bepridil: new calcium antagonists for cardiovascular disorders. ( Hasegawa, GR, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (15.00) | 18.7374 |
| 1990's | 5 (25.00) | 18.2507 |
| 2000's | 12 (60.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schwander, B | 1 |
| Gradl, B | 1 |
| Zöllner, Y | 1 |
| Lindgren, P | 1 |
| Diener, HC | 2 |
| Lüders, S | 2 |
| Schrader, J | 2 |
| Villar, FA | 1 |
| Greiner, W | 1 |
| Jönsson, B | 1 |
| Plosker, GL | 1 |
| Fagard, RH | 4 |
| Staessen, JA | 5 |
| Thijs, L | 4 |
| Celis, H | 2 |
| Birkenhäger, WH | 4 |
| Bulpitt, CJ | 3 |
| de Leeuw, PW | 2 |
| Leonetti, G | 1 |
| Sarti, C | 2 |
| Tuomilehto, J | 3 |
| Webster, J | 2 |
| Yodfat, Y | 2 |
| Kulschewski, A | 1 |
| Hammersen, F | 1 |
| Plate, K | 1 |
| Berger, J | 1 |
| Zidek, W | 2 |
| Dominiak, P | 1 |
| Boulanger, JM | 1 |
| Hill, MD | 1 |
| Owen, A | 1 |
| Johnston, SC | 1 |
| Ishimitsu, T | 1 |
| Honda, T | 1 |
| Ohta, S | 1 |
| Akashiba, A | 1 |
| Takahashi, T | 1 |
| Kameda, T | 1 |
| Yoshii, M | 1 |
| Minami, J | 1 |
| Takahashi, M | 1 |
| Ono, H | 1 |
| Matsuoka, H | 1 |
| Park, JW | 1 |
| Leithäuser, B | 1 |
| Jung, F | 1 |
| Arabidze, G | 1 |
| Babeanu, S | 1 |
| Gil-Extremera, B | 1 |
| Davidson, C | 1 |
| Efstratopoulos, AD | 1 |
| Fletcher, AE | 2 |
| Fogari, R | 1 |
| Jääskivi, M | 1 |
| Kawecka-Jaszcz, K | 1 |
| Nachev, C | 1 |
| Petrie, JC | 1 |
| Seux, ML | 1 |
| Rastenyte, D | 1 |
| Antikainen, R | 1 |
| Forette, F | 1 |
| Goldhaber, A | 1 |
| Palatini, P | 1 |
| Fagard, R | 1 |
| Salpeter, S | 1 |
| Wang, JG | 3 |
| Gong, L | 2 |
| Liu, L | 2 |
| Gasowski, J | 1 |
| Mancini, M | 1 |
| Marotta, T | 1 |
| Ferrara, LA | 1 |
| Spieker, C | 1 |
| Barenbrock, M | 1 |
| Sprakel, B | 1 |
| Buchholz, B | 1 |
| Rahn, KH | 1 |
| Sudhir, K | 1 |
| Jennings, GL | 1 |
| Bruce, A | 1 |
| Hasegawa, GR | 1 |
| Katz, AM | 1 |
| Leach, NM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Peripheral and Cerebral Arterial Flow in Acute Ischemic Stroke: Fimasartan vs. Valsartan vs. Atenolol[NCT02403349] | Phase 4 | 105 participants (Actual) | Interventional | 2012-05-31 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for nitrendipine and Cardiovascular Diseases
| Article | Year |
|---|---|
Eprosartan: a review of its use in hypertension.
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Body Ma | 2009 |
Metabolic neutrality in nitrendipine therapy.
Topics: Blood Glucose; Cardiovascular Diseases; Humans; Hypertension; Lipid Metabolism; Metabolism; Nitrendi | 1991 |
Nicardipine, nitrendipine, and bepridil: new calcium antagonists for cardiovascular disorders.
Topics: Bepridil; Calcium Channel Blockers; Cardiovascular Diseases; Humans; Nicardipine; Nitrendipine; Pyrr | 1988 |
Differential effects of 1,4-dihydropyridine calcium channel blockers: therapeutic implications.
Topics: Angina Pectoris; Calcium; Calcium Channel Blockers; Cardiovascular Diseases; Dihydropyridines; Hemod | 1987 |
12 trials available for nitrendipine and Cardiovascular Diseases
| Article | Year |
|---|---|
Prognostic significance of electrocardiographic voltages and their serial changes in elderly with systolic hypertension.
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Double-Blind Method; Electrocardiography; Fe | 2004 |
Morbidity and Mortality After Stroke, Eprosartan Compared with Nitrendipine for Secondary Prevention: principal results of a prospective randomized controlled study (MOSES).
Topics: Acrylates; Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; B | 2005 |
Morbidity and mortality after stroke--eprosartan compared with nitrendipine for secondary prevention: principal results of a prospective randomized controlled study (MOSES).
Topics: Acrylates; Angiotensin-Converting Enzyme Inhibitors; Cardiovascular Diseases; Data Interpretation, S | 2006 |
MOSES: superiority or noninferiority?
Topics: Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Cerebrovascular Disorders; Clinica | 2006 |
Sublingual application of liquid nitrendipine does not result in critical hypotension in healthy volunteers under phosphodiesterase-5 inhibition.
Topics: Administration, Sublingual; Adult; Angina Pectoris; Blood Pressure; Carbolines; Cardiovascular Disea | 2008 |
Calcium channel blockade and cardiovascular prognosis in the European trial on isolated systolic hypertension.
Topics: Aged; Aged, 80 and over; Calcium Channel Blockers; Cardiovascular Diseases; Double-Blind Method; Dru | 1998 |
Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators.
Topics: Aged; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Complicat | 1999 |
Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group.
Topics: Aged; Alcohol Drinking; Antihypertensive Agents; Asian People; Blood Pressure; Captopril; Cardiovasc | 2000 |
Prognostic significance of serum creatinine and uric acid in older Chinese patients with isolated systolic hypertension.
Topics: Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Calcium Channe | 2001 |
Dihydropyridine calcium-channel blockers for antihypertensive treatment in older patients--evidence from the Systolic Hypertension in Europe Trial.
Topics: Aged; Alcohol Drinking; Calcium Channel Blockers; Cardiovascular Diseases; Dihydropyridines; Double- | 2001 |
Cardiovascular side effects after renal allograft rejection therapy with Orthoclone: prevention with nitrendipine.
Topics: Adult; Blood Pressure; Cardiovascular Diseases; Female; Graft Rejection; Humans; Hypertension; Immun | 1991 |
Cardiovascular-risk reduction: initial diuretic therapy compared with calcium-antagonist (felodipine) therapy for primary hypertension.
Topics: Adult; Aged; Blood Pressure; Calcium Channel Blockers; Cardiovascular Diseases; Cholesterol; Clinica | 1989 |
4 other studies available for nitrendipine and Cardiovascular Diseases
| Article | Year |
|---|---|
Cost-utility analysis of eprosartan compared to enalapril in primary prevention and nitrendipine in secondary prevention in Europe--the HEALTH model.
Topics: Acrylates; Antihypertensive Agents; Cardiovascular Diseases; Cost-Benefit Analysis; Enalapril; Europ | 2009 |
Preventing cerebrovascular and cardiovascular events after stroke: eprosartan or nitrendipine?
Topics: Acrylates; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Calcium Channel Blocker | 2006 |
Cardiorenal protective effects of year-long antihypertensive therapy with an angiotensin-converting enzyme inhibitor or a calcium channel blocker in spontaneously hypertensive rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Aorta; Blood Pressure; C | 2006 |
Calcium-channel blockade and hypertension.
Topics: Aged; Antihypertensive Agents; Calcium Channel Blockers; Cardiovascular Diseases; Diabetes Complicat | 1999 |